IP Library Granted Patent US 8,036,748
Granted Patent B2
US 8,036,748 · App. 12/665,111 · Granted Oct 11, 2011

Ingestible therapy activator system and method

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,036,748
App. No.
12/665,111
Granted
Oct 11, 2011
Kind
B2
Abstract

An ingestible therapy activator system and method are provided. In one aspect, the ingestible therapy activator includes an ingestible device having an effector module to send an effector instruction and a responder module associated with a therapeutic device. The responder module may receive and process the effector instruction, resulting in a response by the therapeutic device. Examples of responses by therapeutic device include activating a therapy, deactivating a therapy, modulating a therapy, and discontinuing a therapy.

Claims (16)

1. A system for providing instructions to a therapeutic device, the system comprising:

an ingestible unit comprising:

a housing; and

an effector module secured within the housing for providing an effector instruction,

wherein the housing dissolves upon contact with the surrounding fluid of a desired target site to release the effector module and the effector module comprises a support structure including two dissimilar materials deposited thereon wherein the dissimilar materials represent a voltage potential difference and provide power for the ingestible unit upon contact with the fluid;

a responder module in communication with the therapeutic device for receiving and processing the effector instruction, wherein the effector instruction alters at least an operation of the therapeutic device; and

a hermetically sealed conductance control module electrically coupled to each of the dissimilar materials for controlling the conductance between the dissimilar materials to generate a unique current signature that presents the effector instruction, wherein the current signature is produced through controlled ionic emission.

2. The system of claim 1 , wherein the ingestible unit further comprises an oral medication.

3. The system of claim 1 , wherein the ingestible unit further comprises a second effector module secured within the housing to provide a second effector instruction.

4. The system of claim 1 , wherein the effector instruction further comprises data.

5. The system of claim 1 , wherein the responder module further comprises a transmitter to transmit at least one of data and signals.

6. The system of claim 1 , further comprising the therapeutic device.

7. The system of claim 6 , wherein the therapeutic device is a cardiac device.

8. The system of claim 7 , wherein the cardiac device is a lead device.

9. The system of claim 6 , wherein the therapeutic device is a selected from a group consisting essentially of an electrode device, a migraine device, a urinary device, and a gastrointestinal device.

10. The system of claim 1 , wherein the responder module comprises at least one of a hardware component and a software component.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2024
From: PROTEUS DIGITAL HEALTH INC.,
To: OTSUKA AMERICA PHARMACEUTICAL, INC.
Reel/Frame 068980/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2024
From: OTSUKA AMERICA PHARMACEUTICAL, INC.
To: OTSUKA PHARMACEUTICAL CO., LTD.
Reel/Frame 068980/0277 →
CHANGE OF NAME Recorded Nov 2, 2012
From: PROTEUS BIOMEDICAL, INC.
To: PROTEUS DIGITAL HEALTH, INC.
Reel/Frame 029228/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2009
From: ZDEBLICK, MARK; JENSEN, MARC; COLLIOU, OLIVIER; STRAND, ANGELA
To: PROTEUS BIOMEDICAL, INC.
Reel/Frame 023680/0160 →